News
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...
Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...
20h
MedPage Today on MSNTwo Drugs Better Than One for Easing Albuminuria in CKD Patients With DiabetesThe standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial ...
Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...
Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...
As President Trump touts his own executive orders to lower drug prices, the Medicare drug price negotiations begun during the Biden administration are continuing behind the scenes. Two companies – ...
Hydro One and ACT Foundation celebrate more than 25,000 students trained in lifesaving skills The ACT Foundation along with ...
The Puerto Rico Science, Technology and Research Trust and the National Institute for Innovation in Manufacturing ...
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Company's Class A and Class B Common Stock payable on July 2, 2025 to shareholders of record on June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results